Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $127.22 -1.09%
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $13.71 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citadel sees year-end stock rally as Wall Street’s biggest buyers return
- Wells Fargo starts On Holding at Overweight, sees growth reaccelerating in 2027
- IREN stock drops on regulatory fears after midterm election
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
